Latest / Cleveland Clinic Cancer Advances
Modified Drug Regimen May Reduce Risks in Allogeneic Hematopoietic Cell Transplant Patients
Betty Hamilton, MD, Interim Director of the Blood and Marrow Transplant (BMT) Program at Cleveland Clinic joins the Cancer Advances podcast to discuss research and findings that were presented at the 2021 American Society of Hematology Annual Meeting (ASH). Listen as Dr. Hamilton discusses graft-versus-host disease and the study that evaluates a new regimen.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.